U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07281456) titled 'Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease' on Dec. 12.
Brief Summary: Background:
Sjogren disease is an autoimmune disease - that is, a disease that causes the body's immune system to attack its own organs and tissues. Sjogren disease can affect the kidneys, lungs, or other organs. It can also cause dry mouth and eyes, fever, joint pain, rashes, and other symptoms. Researchers want to know if a drug approved to treat rheumatoid arthritis and other autoimmune diseases can help people with Sjogren disease.
Objective:
To test a drug (tofacitinib) in people with Sjogren disease.
Eligibility:
...